Beta: Sign in
Shares outstandingAs of 2026-08-03 · filed common shares: 53.62M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.70%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 23.10%
Short ratioDays to cover, as published by FINRA: 15.17
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 62.20%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 58.10%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Loading evidence for AVTX

Rev growth (fwd)

Avg volume (3 months)

Profitability

Gross margin: —
Operating marginFY Dec 25: -123601.69%
Net margin: —
EBITDA marginFY Dec 25: -123018.64%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -36.27%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -32.50%

Growth

Revenue growth (annual YoY): -86.62%
Revenue growth (latest qtr YoY): -100.00%
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales: Sign in
Price / operating cash flow: Sign in
P/FCF: Sign in
EV / revenue: Sign in
EV / EBITDA: Sign in
EPSDiluted, TTM to Jun 26: -4.41
EPS (fwd): Sign in

Financial health

Cash & equivalentsas of Jun 26: $85.38M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $242.00K
Debt / equityas of Jun 26: 0.05%
Current ratioas of Jun 26: 19.31
Quick ratio: —
Operating cash flowTTM to Jun 26: -$68.29M
Free cash flow (six months)Six months: 2026-01-01 to 2026-06-30 · Not annualized: -$37.67M
TTM revenue / diluted share: —

AVTX stock Statistics — Avalo Therapeutics, Inc. filings, insiders & smart money · Instaport